HRS9950 / Jiangsu Hengrui Pharma - LARVOL DELTA

A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs) (clinicaltrials.gov) - P2 | N=54 | Completed | Sponsor: Chengdu Suncadia Medicine Co., Ltd. | Active, not recruiting ➔ Completed | Trial primary completion date: Jul 2024 ➔ Nov 2024

Trial completion • Trial primary completion date • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Safety, Tolerability, Pharmacokinetics(PK), Pharmacodynamics(PD) and Food Effect of HRS9950 in Healthy and CHB Subjects (clinicaltrials.gov) - P1 | N=146 | Completed | Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting ➔ Completed | N=104 ➔ 146

Enrollment change • Trial completion • Hepatitis B • Hepatology • Infectious Disease • Inflammation

A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs) (clinicaltrials.gov) - P2 | N=54 | Active, not recruiting | Sponsor: Chengdu Suncadia Medicine Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Hepatitis B • Hepatology • Infectious Disease • Inflammation

A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs) (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: Chengdu Suncadia Medicine Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatitis B • Hepatology • Infectious Disease • Inflammation

A Phase II Clinical Study of the Efficacy and Safety of HRS9950 Tablets in Chronic Hepatitis B Patients Who Are Virologically Suppressed on Nucleoside or Nucleotide Analogues (NAs) (clinicaltrials.gov) - P2 | N=50 | Not yet recruiting | Sponsor: Chengdu Suncadia Medicine Co., Ltd.

New P2 trial • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Safety, Tolerability, Pharmacokinetics(PK), Pharmacodynamics(PD) and Food Effect of HRS9950 in Healthy and CHB Subjects (clinicaltrials.gov) - P1; N=104; Not yet recruiting; Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Clinical • New P1 trial • Hepatitis B • Infectious Disease